Hone Bio

Executive Summary

Hone Bio is a pre-clinical biotechnology company based in Bristol, UK, developing NanoPilot, a novel antibody-based fusion protein platform designed to redirect lipid nanoparticles (LNPs) away from the liver and toward specific extrahepatic cell types. This technology aims to unlock the potential of LNP-delivered nucleic acid therapies for a wide range of diseases beyond the liver, addressing a key limitation in the field of gene therapy and RNA therapeutics. Founded in 2019, the company operates at the intersection of microbiome and digital health, though its core focus remains on targeted drug delivery. With no disclosed funding rounds or valuation, Hone Bio is at an early stage, but its platform could significantly expand the therapeutic index of LNP-based treatments if validated in preclinical models. The company's success hinges on demonstrating specific extrahepatic targeting and favorable safety profiles in in vivo studies.

Upcoming Catalysts (preview)

• Q1 2027Publication of preclinical in vivo data demonstrating extrahepatic targeting60% success
• Q2 2027Series A funding round or strategic partnership50% success
• Q3 2027IND-enabling studies initiation for lead candidate30% success